CAMBRIDGE, Mass., — Insilico Medicine ("Insilico", HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced that the company has been officially included as a constituent stock of the Hang Seng Composite Index (HSCI), and the company's shares are now eligible for trading via the Stock Connect program including Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, the channels for stock trading and investment between capital market investors in Hong Kong and Chinese Mainland. Insilico’s inclusion in the Stock Connect program will allow qualified Chinese Mainland investors to trade directly, which is expected to further enhance stock liquidity and market attention, strengthen the company's capital market influence, and provide more solid support for continued innovation and sustainable development.
Since Insilico's listing on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, the company's shares have achieved a cumulative gain of 139% compared to the Initial Public Offering price as of midday closing on March 9. Meanwhile, Insilico has been featured in coverage reports from renowned institutions including Morgan Stanley, Southwest Securities, and CITIC Securities, all with "Buy" ratings.
AI-empowered Pipeline Acceleration & Generative AI Ecosystem Enhanced by MMAI Gym Launch
As a pioneer in generative artificial intelligence application for drug discovery, Insilico continues to drive deep integration of cutting-edge AI technology with extensive scientific expertise, building a diversified internal pipeline covering over 40 innovative programs and 28 drug candidates at the IND-enabling stage, of which 12 have received IND clearance.
Since 2026, Insilico has achieved multiple drug development milestones, nominating several preclinical candidates including ISM0676, a novel oral GIPR antagonist achieving 31.3% weight reduction as combination therapy in preclinical studies; ISM5059, a peripheral-restricted NLRP3 inhibitor featuring AI-driven novel chemical core, robust efficacy and excellent safety profiles; and ISM6166, a pan-KRAS inhibitor achieving significant tumor regression in preclinical studies. On the clinical front, Garutadustat (ISM5411), a gut-restricted PHD inhibitor, is being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical trial, and the company has completed first patient dosing.
Beyond small molecule drug innovation, Insilico is also expanding diverse applications of generative AI. With support from Microsoft Foundry, Insilico has open-sourced DORA Community Edition, a multi-agent AI writing assistant that provides content support for academic document generation based on Insilico's proprietary databases with traceable, accurate references. Leveraging Generative Biologics, the biomolecule engineering engine under Pharma.AI, the company continues to empower the development of new modalities in therapeutics including peptides, nanobodies, antibody-drug conjugates (ADCs), and PROTACs.
In addition, Insilico’s MMAI Gym, a specialized training environment designed for biochemistry and other high-barrier specialized domains, was recently launched with the purpose of equipping frontier large language models (LLMs) with stronger professional reasoning and capabilities across expert tasks. As a key component of the company's roadmap toward Pharmaceutical Superintelligence (PSI), MMAI Gym features 1,000+ pharmaceutical and biomedical benchmarks and is equipped with 120 billion tokens of pharmaceutical training data, and systematically enhances model capabilities in real drug research tasks while providing verifiable, standardized evaluation to strengthen scientific reasoning abilities in medicinal chemistry, biology, and clinical scenarios.
Fast-track Delivery in Collaborations & The Second Curve Through Innovation
For business development and global collaboration, Insilico keeps strengthening the strategic partnership network with global innovation leaders, expanding the boundaries of AI application while deepening cooperation models with a quick delivery pace, laying the foundation for rapid future growth and strong expectations.
Since 2026, the company has successively reached innovative drug R&D collaborations with Servier, Qilu Pharmaceutical, and CMS, covering high-demand areas including oncology, metabolism, central nervous system disorders, and autoimmune diseases with a focus on innovative and challenging targets, reaching a total collaboration value exceeding $1 billion. Moreover, Insilico reached pipeline licensing agreements with TaiGen Biotechnology and HygtiaTherapeutics (incubated by Fosun Pharma) in late 2025 and early 2026, with multiple milestones achieved.
As collaboration projects start to deliver, key milestones are achieved. Specifically, MEN2501 (ISM9682), a highly differentiated KIF18A small molecule inhibitor licensed to Menarini in January 2025, successfully achieved IND approval and first patient dosing, triggering milestone payments of USD 3 million and USD 5 million, respectively. ISM4808, an AI-driven PHD inhibitor in collaboration with TaiGen Biotechnology, also recently achieved the first milestone, marked by the enrollment and dosing of the first subject in Phase I clinical trial.
Also, Insilico's MMAI Gym, the specialized large model training platform, achieved value validation in the collaboration with Liquid AI, where the trained model demonstrated SOTA results across multiple drug discovery benchmarks, delivering cloud-scale performance with just 2.6B parameters while operating entirely on private infrastructure. With a flexible membership-based business model, MMAI Gym serves global pharmaceutical companies, biotech firms, AI labs, and cloud service providers, driving the transformation of Insilico from "AI-drivn in-house R&D" to "industry-wide empowerment," building the second curve in business while unlocking more innovation and commercialization opportunities in the global biopharmaceutical intelligence wave.
"Inclusion in Stock Connect represents a significant milestone in Insilico's development journey. China has the world's most vibrant biopharmaceutical innovation ecosystem, and we are honored to provide Mainland investors with a direct opportunity to participate in the AI-enabled transformation of life sciences," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "Moving forward, Insilico will keep the spirit of original innovation and adhere to efficient drug development strategies, leveraging our proprietary, comprehensive Pharma.AI platform and MMAI Gym, the specialized large model training platform recently launched, to drive broader global collaborations and high-efficiency, high-quality pipeline development, bring benefits to all patients and repay the trust of our investors."
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code HKEX: 3696.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com